Background The emergence of drug-eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis. This study was conducted to evaluate the safety and efficacy of sirolimus-eluting cobalt-chrome stents (Firebird 2) for treating patients with coronary artery disease. Methods Sixty-seven patients with de novo or non-stented restenostic coronary lesions were chosen to receive the Firebird 2 stent as the final treatment (Firebird 2 group). Another 49 consecutive patients were implanted with bare cobalt alloyed stents (Driver, Medtronic) within the previous six months and served as historical controls (control group). Baseline clinical characteristics, angiographic features, procedural results, 30-day, 6-month and 12-month clinical follow-up regarding the occurrence of major adverse cardiac events (MACE), as well as the primary endpoint of late lumen loss at 6-month angiographic follow-up were compared between the two groups. Results The demographic characteristics were similar between the two groups despite more patients in the Firebird 2 group who underwent previous percutaneous coronary intervention (22.4% vs 8.2%, P=0.0418) and who had diabetes mellitus (29.9% vs 12.2%, P=0.0253). In the Firebird 2 group, the mean diameter of the reference vessel was smaller ((2.79±0.46) mm vs (2.98±0.49) mm, P=0.0175) and more stents were implanted for each lesion (1.28±0.52 vs 1.10± 0.30, P=0.0060). Other angiographic, procedural results and the device success rate were similar between the two groups. The MACE rate at 30-day and 3-month was the same, but significantly fewer MACE occurred in the Firebird 2 group at 6-and 12-month follow-up (1.5% vs 12.2% at 6 month, P=0.0168; 1.5% vs 26.5% at 12 month, P<0.0001). The primary endpoint of late lumen loss at 6-month angiographic follow-up was significantly reduced in the Firebird 2 group (in-stent: (0.05±0.09) mm vs (0.98±0.61) mm; in-segment: (0.05±0.18) mm vs (0.72±0.59) mm; P<0.0001) than the control group. One patient in the Firebird 2 group had in-segment restenosis (1.3%) while the rate in the control group (38.1%) was significantly higher, P<0.0001. Intravascular ultrasound examination was performed in 70.1% of patients in the Firebird 2 group and revealed that the percentage of volumetric obstruction was (1.26±1.05) %. No stent thrombosis was observed in either group at 12-month follow-up. Conclusion The Firebird 2 sirolimus-eluting cobalt alloyed stent is safe and feasible in treating patients with coronary artery disease.
he emergence of drug-eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis, and DES now appears to be a most promising approach to both mechanically remodel target lesions and biologically reduce neointimal hyperplasia. 1 Clinical studies have shown that the superiority of DES compared with bare metal stents (BMS) to reduce major adverse cardiac events (MACE, defined as cardiac death, non-fatal myocardial infarction or target lesion revascularization), especially regarding the reduction of target lesion revascularization after initial percutaneous coronary intervention (PCI).
by several clinical studies. 5, 6 In comparison with stainless steel, cobalt alloy has a higher radial strength and radiopacity, which allow for the production of a thinner stent strut. 7 However, stents using cobalt alloy as the platform and loaded with sirolimus are still not currently available for clinical application. The purpose of this present study is to provide the first in-human safety and efficacy evaluations of the sirolimus-m eluting cobaltchromium alloyed stents (Firebird 2, MicroPort, Shanghai, China), compared with the bare cobalt alloyed stent (Driver, Medtronic, USA)
METHODS

Study design and patient population
This was a prospective, historically controlled, multi-center study (at 3 centers in China), which was performed between October 2005 and January 2007. The study protocol was approved by the hospital ethic committees and monitored by Division of Biometrics, Center for Cardiovascular Disease Control and Prevention, Ministry of Health, China. Written informed consent was obtained from all patients. Sixty-seven patients with coronary artery disease received the Firebird 2 DES (Firebird 2 group) and 49 consecutive patients with Driver stent implantation served as controls. The inclusion criteria are as follows: maximally 2 de novo or non-stented restenotic coronary lesions; reference vessel diameter 2.25-4.0 mm, length < 30 mm at target lesion; patient willing to sign inform consent and receive both clinical and angiographic follow-up. The exclusion criteria include acute myocardial infarction (AMI) within 1 week; left main coronary artery disease (diameter stenosis ≥ 50%); angiographic thrombus containing lesion; lesion unable to be pre-dilated due to severe calcification or tortuosity; >2.5 mm in diameter side branch present; total occlusion lesion (TIMI 0 grade); NYHA>3 or LVEF<30%; expected life < 12 months. All patients received aspirin (100 mg/d) and clopidogrel (75 mg/d) at least 2 days before the procedure. Thereafter, aspirin (100 mg/d) was continued indefinitely and clopidogrel (75 mg/d) was continued for at least 6 months after the procedure. 1-, 3-, 6-, and 12-month clinical and 6-month angiographic follow-up were scheduled after stent implantation.
Study device
The Firebird 2 stent is an open cell designed balloon expandable stent, with the cobalt-chromium alloy as the platform loaded with sirolimus (9 µg/mm stent length) in combination with the styrene-butylenes-styrene (SBS) polymer. The in vitro assays have shown that about 50% of the drug elutes in 1 week and about 90% in 1 month. The length of the stent was 13, 18, 23, 29, 33 mm, with diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
Follow-up and study endpoints
Clinical evaluation was scheduled at 1, 3, 6 and 12 months after the initial procedure. Angiographic follow-up was obtained at baseline and 6-month. Intravascular ultrasound (IVUS) was performed at the discretion of the doctors. The primary study endpoint of in-stent late lumen loss at 6-month angiographic follow-up was compared between the two groups and a major secondary endpoint of in-stent percentage of volume obstruction at 6-month by IVUS was used to assess the neointimal hyperplasia for Firebird 2 DES only. Other secondary endpoints included angiographic binary restenosis at 6-month, MACE at 1-, 6-and 12-month clinical follow-up and stent thrombosis. Non-Q-wave myocardial infarction (MI) was defined as elevation of creatine kinase (CK)-MB >2 times normal in the absence of new pathological Q-wave and Q-wave MI was defined as elevation on CK-MB >2 times the normal range and new pathological Q-wave in electrocardiogram. Procedural success was defined as achieving <20% residual stenosis and TIMI 3 flow of all lesions attempted without major clinical complications (including death, MI and emergency coronary artery bypass surgery) during hospitalization. Device success was defined as the successful deployment of a stent that covers the target lesion completely with the residual stenosis of less than 20%. 8, 9 Stent thrombosis was defined as either definite or probable stent thrombosis. Definite stent thrombosis was defined as the presence of angiographic thrombus in a stent that previously had been successfully deployed. Angiographic thrombus was defined as complete occlusion (thrombosis in myocardial infarction grade 0 or 1 flow) or evidence of flow-limiting thrombus (ovoid or linear filling defect) within or immediately adjacent to the stent. Probable stent thrombosis is defined as unexplained sudden cardiac death or Q-wave MI in the distribution of the stented artery.
Angiographic and IVUS analysis
Coronary angiograms were obtained in multiple views after an intra-coronary injection of nitroglycerin. Offline quantitative analyses of pre-procedural, post-procedural and six-month follow-up angiographic data were performed by an independent core laboratory. Quantitative coronary angiography (QCA) was performed with QUANTCOR QCA (CAAS II) version 5.0 (Pie Medical Imaging, the Netherlands). Late lumen loss was defined as the difference between the minimal lumen diameter (MLD) after procedure and at six-month angiographic follow-up. Restenosis was defined as ≥ 50% diameter stenosis at follow-up, and was classified as in-stent if inside of the stent or in-segment if located at the stented segment or up to 5 mm proximal or distal to the stents. IVUS images were acquired by using automated pullback at 0.5 mm/s after intracoronary nitrates with a commercially available imaging system (Galaxy II, Boston Scientific, USA). Two-dimensional and volumetric IVUS analysis was performed with commercially available software (VIVI Viewer 1.6, Beijing JX Digital Wave Co. LTD, China) according to previously validated and published protocols. 10 Vessel, stent, lumen, and neointimal volumes were computed for the stented segment as well as stent margins 5 mm distal and proximal to the stent. Percentage of volumetric obstruction was defined as neointimal volume index (NVI) divided by stent volume index (SVI).
Statistical analysis
The assumed in-stent late lumen loss was (0.62±0.46) mm and (0.93±0.59) mm in the Firebird 2 and control groups respectively. 11 To guarantee the 2 sides P<0.05 and power of 80%, at least 48 lesions were included in each group. For considering 30% of samples dropout during angiographic follow-up, the smallest lesion size was finally 69 for each group.
All data were collected and sent to an independent organization for date safety and monitoring. Continuous variables were presented as mean±standard deviation (SD) and were compared using the Student's t test. Categorical variables were expressed as rates or proportions and were compared by the Pearson chi-square test or the Fisher's exact test. All analyses were performed on a per-lesion basis. MACE-free survival distribution was calculated by the Kaplan-Meier method. The log-rank test was used to compare MACE-free survival between the two groups. A 2-sided probability P value <0.05 was considered statistically significant. All calculations were performed by use of SAS ® 9.13 software package (NC, USA).
RESULTS
Baseline and procedure characteristics
Baseline patient characteristics were similar in both groups, except more patients in the Firebird 2 group had previous PCI history and diabetes compared with the control patients ( Table 1 ). The baseline lesion characteristics, QCA analysis and procedural results were similar between the two groups, except that the diameter of the reference vessel was smaller and more stents were implanted for each lesion in the Firebird 2 group (Table  2) . No procedural complications occurred and the device success rate was 100% in both groups.
Clinical follow-up
All patients in both groups finished 30-day, 6-and 12-month clinical follow-up. No MACE occurred at the 30-day clinical follow-up. At the 6-month follow-up one patient in the Firebird 2 group had target lesion revascularization by implanting another sirolimus-eluting stent (Firebird, Microport), and 6 patients in the control group had repeated PCI for the target lesion. The 6-and 12-month MACE was significantly reduced in the Firebird 2 group as compared with the control group ( Table 3) . The MACE-free survival rate was significantly improved in the Firebird 2 group (Fig. 1) . Neither a definite nor probable stent thrombosis event was reported at 12-month follow-up in either group.
Angiographic follow-up
Fifty-eight patients (86.6%) in the Firebird 2 group completed the 6-month angiographic follow-up and seventy-seven lesions were analyzed. In the control group, all 49 patients underwent angiographic follow-up (Table  4 ). The primary endpoint of in-stent late lumen loss was Table 3 . Clinical follow-up results (Fig. 2) ), and the in-stent minimal lumen diameters during 6-month follow-up were (2.68±0.45) mm and (1.84±0.75) mm in the Firebird 2 group and control group respectively (Fig. 3) . In the Firebird 2 group, no patient had in-stent restenosis, but one patient had in-segment angiographic restenosis (1.3%), a significantly lower incedence when compared with the control group; 36.5% and 38.1% respectively (all P<0.0001).
IVUS examinations
In the Firebird 2 group, 47 patients (70.1%) with 60 lesions (68.2%) received IVUS examinations at 6-month angiographic follow-up. Quantitative analysis showed that the neointimal volume in the stented area was (2.87 ±2.95) mm 3 and the percentage of volume obstruction was (1.26±1.05) %. The late incomplete stent apposition was found in 5 lesions (8.3%) and no evidence of stent thrombosis was found by the IVUS. Historical controls did not undergo IVUS examinations.
DISCUSSION
The present study is the first clinical experience with implanting sirolimus-eluting cobalt-chromium stents in China. The results showed that the Firebird 2 stent is a promising therapeutic option for treating patients with coronary artery disease due to its efficacy in preventing of neointimal proliferation, associated restenosis and clinical adverse events. The safety of the Firebird 2 stent was also proved as there were no reports of stent thrombosis for 12 months although the dual antiplatelet therapy was only requested for 6 months in Firebird 2 group.
The bare cobalt chromium metal stent has been shown to reduce the MACE rate as compared to the routine bare stainless steel stents. 5, 7 When compared with the DES with the platform of stainless steel, the bare cobalt-chromium stent was more cost-effective in selected patients with coronary artery disease in the BASKET randomized trial. 6 The improved clinical outcome after implanting cobalt alloyed stents may result from their thinner strut and less metal coverage.
As a new generation of the Firebird DES family, the Firebird 2 stent uses cobalt-chromium alloy as the stent platform and was loaded with sirolimus on the SBS polymer. The dosage of sirolimus was 9 µg/mm of stent length, and in vitro testing indicated that about 50% of the drug would be released within 1 week and 90% by 1 month. Prior studies using the first generation of Firebird DES with the same dosage of sirolimus have identified its efficacy and safety in treating unselected or diabetic patients with coronary artery disease. 2, [12] [13] [14] Combining the improved stent platform and effective anti-proliferation drug, the efficacy of the Firebird 2 stent was first proven in the present study. At 6-month angiographic follow-up the primary endpoint of in-stent late lumen loss in the Firebird 2 group was only (0.05± 0.09) mm, significantly lower than that in the control group ((0.98±0.61) mm (P<0.0001)) and similar to a previously published study using the same cobalt alloyed bare stent. 15 In the DES group of the SIRIUS, E-SIRIUS and TAXUS-IV trials the mean in-stent late losses observed were (0.17±0.45) mm, (0.20±0.38) mm and (0.39±0.50) mm, with a TLR rate of 4.1%, 7.0% and 3.7%, respectively. [16] [17] [18] In the present study, both in-stent late lumen loss and TLR rate were lower than those in previous studies using drug eluting stainless metal stent. In the current study, no patient had in-stent restenosis in the Firebird 2 group at the 6-month angiographic follow-up. Only one patient had in-segment restenosis (1.3%) after receiving the Firebird 2 stent. Compared with the control group, both in-stent and in-segment restenosis were significantly reduced at the 6-month angiographic follow-up (in-stent: 0 vs 36.5%; in-segment: 1.5% vs 38.1%, all P<0.0001).
Neointimal volumetric measurements from IVUS analysis may better estimate the magnitude of neointimal growth after stenting than the indes of late loss 16 and has now become a new standard to evaluate the effect of DES. 17 A total of 70.1% of the patients in the Firebird 2 group received the IVUS examination at the time of angiographic follow-up and the percentage of volumetric obstruction was (1.26 ± 1.05) %. Findings from the SIRIUS study indicated that the 9-month volumetric obstruction percentage of the Cypher stent was 3.1% 18 and, in the Taxus II study, this index was (7.8±9.9) % for slow-release Taxus stents and (7.8 ± 9.7) % for moderate-release Taxus stents. 19 In the Taxus IV study the 9-month volumetric obstruction percentage was (12.2± 12.4) % for slow-release Taxus stents. 20 Compared to these results, the Firebird 2 stent had a lower volumetric obstruction percentage. The efficacy of inhibiting neointimal hyperplasia of this new generation of DES could also be concluded from the IVUS examination, although the follow-up duration was a little shorter than the previous studies.
Stent thrombosis in the DES era is a disturbing problem due to its catastrophic consequences for individual patient; although the incidence is rare. 21 The cause of stent thrombosis after implanting a DES is multifactorial with delayed endothelialization or healing in combination with other clinical and procedural risk factors. 22 Premature discontinuation of dual antiplatelet therapy was strongly associated with stent thrombosis, 23 but the appropriate duration of dual antiplatelet therapy has not been determined by large-scale randomized clinical trials. 24 In this study, all patients in the Firebird 2 group received dual antiplatelet therapy for at least 6 months and most of them (91.0%) stopped clopidogrel after getting an optimal 6-month angiographic follow-up. No stent thrombosis event was reported at the 12-month clinical follow-up.
Of note, in 8.3% of the lesions in the Firebird 2 group which underwent IVUS examination, the stents were found incompletely apposed to the vessel wall. In these patients, dual anti-platelet therapy with clopidogrel and aspirin was encouraged to be continued indefinitely. Previous study indicated that the prevalence of late stent malapposition occurred in 16.3% of the patients receiving the Cypher stent, 25 which is much higher than that in our study. Although stent malapposition may be the causes of very late stent thrombosis, a previous study by Degertekin et al 26 showed that incomplete stent apposition after implantation of a sirolimus-eluting stent was not associated with adverse events at late follow-up.
The limitations of the study are as follows: the control group was selected from a historical database and the 6-month angiographic and 12-month clinical follow-up may be too short to evaluate the long-term safety and efficacy of a DES. And patients included in the present study were strictly selected by their angiographic and clinical characteristics. Large-scale randomized trials in unselected patients are still needed to determine the long-term outcome of this new generation DES.
In conclusion, based on the present clinical, angiographic and IVUS results, the Firebird 2 stent appears to be a safe and feasible treatment option for patients with coronary artery disease.
